Thu,27 October 2011
Patients in the UK suffering from a rare life-threatening heart condition, pulmonary arterial hypertension (PAH), could soon be offered a new treatment.
Drug company Pfizer has launched Revatio for use in patients with this condition which produces abnormal pressure levels in the blood vessel that leads from the heart to the lungs.
Sufferers experience breathlessness, fainting, chest pains and tiredness. The condition affects about 100,000 people worldwide and is most commonly seen in women between the ages of 20 and 40.
|
